Esposito Pamela 4

4 · Kymera Therapeutics, Inc. · Filed Jan 20, 2026

Form 4

Period: 2026-01-20

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-20$31.20/sh+3,000$93,600→ 3,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-20$49.10/sh+2,500$122,750→ 5,500 total
Sale
Common Stock
[F1][F2]
2026-01-20$66.68/sh−400$26,672→ 5,100 total
Sale
Common Stock
[F1][F3]
2026-01-20$67.99/sh−4,900$333,145→ 200 total
Sale
Common Stock
[F1]
2026-01-20$68.52/sh−200$13,704→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-01-20−3,000→ 10,000 total
Exercise: $31.20Exp: 2034-06-18→ Common Stock (3,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-01-20−2,500→ 5,000 total
Exercise: $49.10Exp: 2031-06-15→ Common Stock (2,500 underlying)

Footnotes (4)

[F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.40 to $66.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.47 to $68.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The shares underlying this stock option are fully vested and exercisable.

Signature

/s/ Bruce Jacobs, as Attorney-in-Fact|2026-01-20

Documents

1 file